 A proof-of-concept study in refractory SLE patients to assess the immunological consequences of a combination treatment with rituximab anti-CD20 and belimumab anti-BAFF to achieve long-term B-cell depletion. The immunological and clinical monitoring of refractory SLE patients will be monitored and the safety and feasibility of this combination treatment evaluated. 